Telik (TELK) says it's completed its End of Phase 2 meeting with the FDA for its MDS treatment...
Telik (TELK) says it's completed its End of Phase 2 meeting with the FDA for its MDS treatment Telintra, with a preliminary agreement reached regarding the design of a Phase 3 trials. In order to focus its resources on the registration program, Telik has decided to stop further enrollment in its ongoing Phase 2 exploratory trials.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs